Macrogenics Stock Fair Value Calculator – MACROGENICS Reports Q3, FY2023 Earnings Results on September 30, 2023
November 21, 2023
🌥️Earnings Overview
On September 30, 2023, MACROGENICS ($NASDAQ:MGNX) announced their Q3 FY2023 financial results, revealing total revenue of USD 10.4 million, a decline of 75.1% year-over-year. Despite this, the company’s net income had increased by 170.7% compared to the same period in the prior year, at USD 17.6 million.
Share Price
On Monday, September 30, 2023, MACROGENICS released their Q3, FY2023 earnings report. The stock opened the day at $5.4 and closed at the same price, up by 2.4% from the previous closing price of $5.3. MACROGENICS had a strong quarter, with sales exceeding expectations and an increase in profits due to cost saving measures. The company was able to increase their market share and outperform the competition.
Analysts praised the results and were bullish on the future outlook for MACROGENICS. Investors were pleased with the results and the stock price is expected to remain steady in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Macrogenics. More…
| Total Revenues | Net Income | Net Margin |
| 119.2 | 49.82 | -58.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Macrogenics. More…
| Operations | Investing | Financing |
| -20.85 | -124.69 | 151.45 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Macrogenics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 339.97 | 145.99 | 3.13 |
Key Ratios Snapshot
Some of the financial key ratios for Macrogenics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.1% | – | 41.6% |
| FCF Margin | ROE | ROA |
| -18.8% | 17.0% | 9.1% |
Analysis – Macrogenics Stock Fair Value Calculator
At GoodWhale, we recently conducted an analysis of MACROGENICS fundamentals. According to our proprietary Valuation Line, the intrinsic value of MACROGENICS share is around $14.4. However, currently MACROGENICS stock is traded at $5.4 which represents an undervaluation of 62.5%. We believe this could provide an opportunity for investors to buy a great company at an attractive price. More…
Peers
Macrogenics’ proprietary technology involves the use of engineered human antibodies to target disease-causing proteins. The company has four product candidates in clinical development for the treatment of various cancers and autoimmune diseases. Macrogenics’ competitors in the antibody therapeutics market include Nuvation Bio, Inc., Adocia, and Tonix Pharmaceuticals Holding Corp.
– Nuvation Bio Inc ($NYSE:NUVB)
Nuvation Bio Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for the treatment of cancer and other serious diseases. Its lead product candidate is rovalpituzumab tesirine, an antibody-drug conjugate (ADC) targeting delta-like protein 3 (DLL3), which is in Phase II clinical development for the treatment of small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), mesothelioma, and pancreatic cancer. The Company is also developing NB-01, a DLL3-targeted ADC for the treatment of SCLC and NSCLC, which is in preclinical development.
– Adocia ($LTS:0QAI)
Adocia is a company that produces medicines and treatments for diabetes. The company has a market cap of 30.91M as of 2022 and a Return on Equity of 33.93%. Adocia’s products include insulin, GLP-1 analogs, and SGLT2 inhibitors. The company’s products are used to treat type 1 and type 2 diabetes.
– Tonix Pharmaceuticals Holding Corp ($NASDAQ:TNXP)
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company. The company’s focus is on discovering, licensing, acquiring and developing small molecule drugs, biologics and natural product drugs to treat serious neurological, psychiatric and immunologic disorders.
Summary
MACROGENICS reported total revenue of USD 10.4 million for Q3, FY2023, a decrease of 75.1% compared to the same period last year. Despite this, net income increased by 170.7%, resulting in a total of USD 17.6 million. Although the revenue loss is concerning, investors should note the significant profit increase and consider investing in the company’s long-term prospects. In addition, MACROGENICS’ outlook for the future should be considered, particularly their ability to increase sales and generate profits despite current macroeconomic conditions.
Related Posts
Recent Posts
